Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.68 |
| ▸ | CTSD | P07339 | 12/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14348054 | 1.00 | BACE1 (0.68) | BACE1CTSDBCHECYP3A4 | |
| SCHEMBL5652580 | 1.00 | BACE1 (0.68) | BACE1CTSDBCHECYP3A4 | |
| Hydrochloric Acid SCHEMBL3349741 | 0.99 | BACE1 (0.67) | BACE1CTSDBCHECYP3A4 | |
| Hydrochloric Acid SCHEMBL3349738 | 0.99 | BACE1 (0.67) | BACE1CTSDBCHECYP3A4 | |
| SCHEMBL5648349 | 0.94 | BACE1 (0.67) | BACE1CTSDBCHECYP3A4 | |
| SCHEMBL5648355 | 0.94 | BACE1 (0.67) | BACE1CTSDBCHECYP3A4 | |
| SCHEMBL14348050 | 0.94 | BACE1 (0.67) | BACE1CTSDBCHECYP3A4 | |
| Hydrochloric Acid SCHEMBL4666410 | 0.93 | BACE1 (0.66) | BACE1CTSDBCHECYP3A4 | |
| Hydrochloric Acid SCHEMBL5648530 | 0.93 | BACE1 (0.66) | BACE1CTSDBCHECYP3A4 | |
| Hydrochloric Acid SCHEMBL5648528 | 0.93 | BACE1 (0.66) | BACE1CTSDBCHECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| US-7144897-B2 | Hydroxy alkyl amines | Elan Oharmaceuticals, Inc. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20030166717-A1 | Hydroxy alkyl amines | FRESKOS JOHN (US) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166717-A1 | Hydroxy alkyl amines | PSEN1, MAOA, PSEN2 | BACE1 47/4885CTSD 3148/4885BCHE 37/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | BACE1 67/4885CTSD 2851/4885BCHE 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.